Kiltearn Partners LLP Bristol Myers Squibb CO Transaction History

Kiltearn Partners LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $7,631 - $4.51 Million	-58,700 Reduced 14.38%	349,500 $24.8 Million
Q2 2022 Aug 09, 2022	SELL	$72.62 - $79.98 $10.6 Million - $11.7 Million	-146,300 Reduced 26.38%	408,200 $31.4 Million
Q1 2022 Apr 29, 2022	SELL	$61.48 - $73.72 $116,812 - $140,068	-1,900 Reduced 0.34%	554,500 $40.5 Million
Q4 2021 Feb 10, 2022	SELL	$53.63 - $62.52 $1.07 Million - $1.25 Million	-20,000 Reduced 3.47%	556,400 $34.7 Million
Q3 2021 Nov 09, 2021	SELL	$59.17 - $69.31 $656,787 - $769,341	-11,100 Reduced 1.89%	576,400 $34.1 Million
Q2 2021 Aug 13, 2021	BUY	$61.91 - $67.42 $36.4 Million - $39.6 Million	587,500 New	587,500 $39.3 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Kiltearn Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Kiltearn Partners LLP with notifications on news.